摘要:
A heterocycle-containing carbonic acid derivative represented by the following general formula (I): ##STR1## or a physiologically acceptable salt thereof which exhibits an excellent preventive and therapeutic effect against various diseases, and an intermediate which is useful for the production of the heterocycle-containing carbonic acid derivative.
摘要:
The present invention provides a medicament exhibiting excellent retinoic acid receptor agonism.A Carboxylic acid derivative having a fused ring which is represented by the following formula or a pharmacologically acceptable salt thereof: ##STR1## {wherein the symbol ##STR2## represents a single bond or a double bond; X, Y, Z, P, Q, U, V and W are each a group represented by the formula: --O-- or --S--, or a group represented by the formula: ##STR3## [wherein R.sup.k (k: 1 to 8) is hydrogen, halogeno, optionally substituted lower alkyl or the like, with either of R.sup.7 and R.sup.8 being a group represented by the formula: ##STR4## (wherein A and B are each independently an optionally substituted aromatic hydrocarbon ring or an optionally substituted unsaturated heterocycle; and D is optionally protected carboxyl)]}.
摘要翻译:本发明提供了显示出优异的视黄酸受体激动作用的药物。 具有由下式表示的稠环的羧酸衍生物或其药理学上可接受的盐:其中符号表示单键或双键; X,Y,Z,P,Q,U,V和W分别是由下式表示的基团:-O-或-S-,或由下式表示的基团:[其中R k(k:1至8) 是氢,卤素,任选取代的低级烷基等,其中R 7和R 8中的任一个是由下式表示的基团:(其中A和B各自独立地是任选取代的芳族烃环或任选取代的不饱和杂环; D 任选保护羧基)]}。
摘要:
The present invention provides a medicament exhibiting excellent retinoic acid receptor agonism. A Carboxylic acid derivative having a fused ring which is represented by the following formula or a pharmacologically acceptable salt thereof: {wherein the symbol represents a single bond or a double bond; X, Y, Z, P, Q, U, V and W are each a group represented by the formula: —O— or —S—, or a group represented by the formula: [wherein Rk (k: 1 to 8) is hydrogen, halogeno, optionally substituted lower alkyl or the like, with either of R7 and R8 being a group represented by the formula: (wherein A and B are each independently an optionally substituted aromatic hydrocarbon ring or an optionally substituted unsaturated heterocycle; and D is optionally protected carboxyl)]}.
摘要翻译:本发明提供一种显示出优异的视黄酸受体激动作用的药物。具有下式表示的稠环的羧酸衍生物或其药理学上可接受的盐:{其中符号表示单键或双键; X,Y,Z,P,Q,U,V和W分别是由下式表示的基团:-O-或-S-,或由下式表示的基团:[其中R k(k:1至8) 是氢,卤素,任选取代的低级烷基等,其中R 7和R 8中的任一个是由下式表示的基团:(其中A和B各自独立地是任选取代的芳族烃环或任选取代的不饱和杂环; D 任选保护羧基)]}。
摘要:
The present invention provides a medicament exhibiting excellent retinoic acid receptor agonism.A Carboxylic acid derivative having a fused ring which is represented by the following formula or a pharmacologically acceptable salt thereof: ##STR1## {wherein the symbol ----- represents a single bond or a double bond; X, Y, Z, P, Q, U, V and W are each a group represented by the formula: --O-- or --S--, or a group represented by the formula: ##STR2## [wherein R.sup.k (k:1 to 8) is hydrogen, halogeno, optionally substituted lower alkyl or the like, with either of R.sup.7 and R.sup.8 being a group represented by the formula: ##STR3## (wherein A and B are each independently an optionally substituted aromatic hydrocarbon ring or an optionally substituted unsaturated heterocycle; and D is optionally protected carboxyl)]}.
摘要:
A spectrophotometer 10 includes built-in detector 24 and external detector 32. When a mountable/removable optical path switcher 23a is installed in a specimen chamber 23, measurement based on detection signals from built-in detector 24 is replaced by measurement based on detection signals from external detector 32. The spectrophotometer further includes a measurement data threshold-value storage unit 51 that stores threshold value T for measurement data from built-in detector 24 or external detector 32, and a light-receiving detector recognition unit 52 that recognizes which detector is able to receive the measuring light beam based on the results of a comparison between threshold value T and measurement data from built-in detector 24 or external detector 32 while the measuring light beam is being introduced into specimen chamber 23.
摘要:
To enable alignment of a magnetic pattern of a pair of master disks and a magnetic recording medium, each of the master disks has at least a pair of alignment marks disposed outside the region of the magnetic pattern. The master disks can be optically transparent or semi-transparent. The master disks can be aligned while the alignment marks are externally observed.
摘要:
The present invention provides a diuretic, sodium ion-excreting agent, medicament for preventing or treating hypertension, medicament for preventing or treating ischemic cardiac diseases, medicament for preventing or treating congestive cardiac insufficiency or medicament for preventing or treating renal diseases, which comprises γ-tocotrienol.
摘要:
Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a —CONH— group or a group represented by the formula —CR6═CR7— in which R6 and R7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.
摘要:
The precision of phase difference obtained by a phase difference calculating unit is improved by correction through outputs of a frequency ratio calculating unit and a temperature calculating unit considering that the phase or time difference of each output signal of a vibration sensor indicating the mass flow or density of a fluid is a function of the temperature and axial force on a measurement pipe, or that the axial force is a function of the ratio between two resonant frequencies.
摘要:
An aminobenzoic acid derivative represented by the following formulas (I-2) or (I-3), or a pharmacologically acceptable salt thereof, which exhibits a serotonin antagonism and an acetylcholine release accelerating activity at a well-balanced activity ratio and which is efficacious as a drug for patients with gastrointestinal unindentified complaints: ##STR1## wherein R.sup.1 represents a group such as an alkynyl or cyanoalkyl group; R.sup.2 represents a group such as an amino or acylamino group; R.sup.3 represents a halogen atom; X represents --O-- or --N--; and A represents an oxygen or sulfur atom.